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Bordetella bronchiseptica is closely related to Bordetella pertussis, which produces respiratory disease primarily 
in mammals other than humans. However, its importance as a human pathogen is being increasingly recog­
nized. Although a large amount of research on Bordetella has been generated regarding protein virulence 
factors, the participation of the surface lipopolysaccharide (LPS) during B. bronchiseptica infection is less 
understood. To get a better insight into this matter, we constructed and characterized the behavior of an LPS 
mutant with the deepest possible rough phenotype. We generated the defective mutant B. bronchiseptica LP39 
on the waaC gene, which codes for a heptosyl transferase involved in the biosynthesis of the core region of the 
LPS molecule. Although in B. bronchiseptica LP39 the production of the principal virulence determinants 
adenylate cyclase-hemolysin, filamentous hemagglutinin, and pertactin persisted, the quantity of the two latter 
factors was diminished, with the levels of pertactin being the most greatly affected. Furthermore, the LPS of 
B. bronchiseptica LP39 did not react with sera obtained from mice that had been infected with the parental 
strain, indicating that this defective LPS is immunologically different from the wild-type LPS. In vivo exper­
iments demonstrated that the ability to colonize the respiratory tract is reduced in the mutant, being effectively 
cleared from lungs within 5 days, whereas the parental strain survived at least for 30 days. In vitro experiments 
have demonstrated that, although B. bronchiseptica LP39 was impaired for adhesion to human epithelial cells, 
it is still able to survive within the host cells as efficiently as the parental strain. These results seem to indicate 
that the deep rough form of B. bronchiseptica LPS cannot represent a dominant phenotype at the first stage of 
colonization. Since isolates with deep rough LPS phenotype have already been obtained from human B. 
bronchiseptica chronic infections, the possibility that this phenotype arises as a consequence of selection 
pressure within the host at a late stage of the infection process is discussed.
Bacterial surface polysaccharides are important contributors 
to the processes of bacterium-host interaction, including sym­
biotic and pathogenic relationships (30). Among these poly­
saccharides, the lipopolysaccharide (LPS) is the major compo­
nent of the outer membrane of gram-negative bacteria. The 
LPSs of the three most studied Bordetella species, B. pertussis, 
B. parapertussis, and B. bronchiseptica, share basic structural 
features in that they each have a lipid A domain and a 
branched-chain core oligosaccharide. However there are dif­
ferences, since B. parapertussis and B. bronchiseptica synthesize 
an O-antigen structure consisting of a polymer of the single 
sugar residue 2,3-di-lV-acetylgalactosaminuronic acid, whereas 
B. pertussis does not (31).
B. bronchiseptica is currently acquiring relevance because of 
its increased importance as a human pathogen (20, 48). This 
microorganism colonizes the ciliated epithelium of the respi­
ratory tract of the host and establishes chronic infections (20). 
It has been speculated that the development of such chronic 
infections may partially depend on the ability of bacteria to 
develop adaptive phenotypic changes in response to variable 
stimuli. This bacterial capacity could be related to two mem­
bers of the two-component family of signal transduction pro­
tein, the bvg (Bordetella virulence gene) (4, 13, 16, 34) and ris 
(regulator of intracellular stress response) loci (5, 9, 20, 26). In 
agreement with this hypothesis, it was reported that in a pa­
tient with bronchopneumonia in whom B. bronchiseptica per­
sisted over a period of 2 years, bacteria isolated from the initial 
period of infection produced toxins and adhesins (14, 22, 27), 
while successive isolates produced only adhesins (20).
Concomitant with this variation, the lipopolysaccharide 
structure shifts from a smooth to a rough/deep rough pheno­
type (21). The same LPS phenotypic change along the course 
of the infection was observed in another human patient with 
persistent B. bronchiseptica infection (unpublished results). 
Bacterial isolates obtained from different hosts also present 
different lengths of LPS molecules (29), pointing out that the 
LPS variation in vivo might be common in long-term infec­
tions. In addition, the observation that LPS structure varies in 
vivo suggests that this molecule plays different roles during the 
different stages of B. bronchiseptica infection (6, 23).
In other gram-negative bacteria, it was demonstrated that 
the LPS structure strongly influences the synthesis and/or se­
cretion of certain proteins (7, 10, 15, 40, 44). In the case of 
Bordetella, current evidence indicates that the expression of 
both components, LPS and protein virulence determinants, is 
modified by the environment (13, 32, 34, 42). At present, how­
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ever, the linkage between the different structures of the LPS, in 
particular the deep rough phenotype, with the expression of 
virulence factors and its significance in the whole infection 
process remain to be established.
In order to gain an insight into the role of LPS in B. bron­
chiseptica infection, we constructed the deepest possible rough 
LPS phenotype by site-specific insertional mutagenesis on the 
waaC gene, which codes for the glycosyltransferase responsible 
for the addition of the first heptose residue to 3-deoxy-D- 
»Muno-octulosonic acid (15, 31, 36). The B. bronchiseptica 
waaC mutant obtained was characterized within the frame­
work of virulence determinant production and its in vitro and 
in vivo behavior.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Escherichia coli strains DH5a (Be­
thesda Res. Lab) and S17-1 (37) were cultured in Luria-Bertani (LB) medium 
supplemented, when appropriate, with ampicillin or kanamycin at a final con­
centration of 200 or 25 pg ml-1, respectively. B. bronchiseptica strain 9.73 
(Collection de l’Institut Pasteur designation) was grown on Bordet Gengou agar 
(Difco) supplemented with 15% (vol/vol) defibrinated fresh sheep blood (BGA 
medium) at 36°C for 48 h. Then it was replated in the same medium for 24 h. For 
mutant selection, BGA was supplemented with streptomycin (200 pg ml-1) and 
kanamycin (75 pg ml-1). For LPS extraction, subcultures were grown in Stainer- 
Scholte (SS) liquid medium (39) for 20 h at 36 C until the optical density 
measured at 650 run reached 1.0.
In order to label bacteria to be able to study bacterial infection of mice, we 
introduced plasmid pGB5P'l (45), which codes for kanamycin resistance and for 
the green fluorescent protein, into the wild-type B. bronchiseptica strain by 
conjugation. This plasmid was kindly provided by Alisson Weiss (Department of 
Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati). 
For immunoblot analysis, bacteria grown in BGA were resuspended in saline at 
a concentration of 2 X 1010 CFU ml-1, diluted in Laemmli buffer (28), and 
boiled for 15 min.
PCR and recombinant DNA techniques. Based on previously reported con­
sensus sequences (2, 3, 7,16, 36) (B. bronchiseptica cosmid BbLPS'l AJ007747), 
we designed two single-stranded oligonucleotide primers, waaCp? (5'-TTCAIC 
AGCCCCTG-3', where I is inosine) and waaCpr (5'-CCAGATTGACGGGT- 
3'). These two oligonucleotides were provided by DNAgency, Inc. (Malvern, 
N.Y.). We then amplified a 200-bp fragment corresponding to an internal se­
quence of the waaC gene. This PCR product was cloned into the shuttle plasmid 
pGem T-Easy (Apr, lacZ'. Promega). After ligation, a recombinant fragment 
from this plasmid was released with E'coRI and cloned into the EcoRI site of the 
Bordetella suicide plasmid pK'lSmob (Kmr) (35).
We performed conjugation incubations in BGA plus 10 mM MgCl2, using B. 
bronchiseptica 9.73 Smr as the recipient and E. coli SI7-1 containing the recom­
binant suicide plasmid as the donor, and thereafter colonies were selected for 
single genetic crossovers on kanamycin plus streptomycin. We then analyzed the 
detergent sensitivity of the resultant colonies of transconjugants on Stainer- 
Scholte solid medium (agar 1.5% [wt/vol]; Sigma Chemical Co.) supplemented 
with 0.02% (wt/vol) sodium dodecyl sulfate (SDS). Genomic DNAs from the 
SDS-sensitive colonies, hereafter referred to as B. bronchiseptica waaC mutants, 
were also probed by Southern hybridization for the presence of the expected 
DNA structure.
Southern hybridization. We performed Southern hybridizations (33) using a 
probe labeled with digoxigenin-conjugated waaCpf and waaCpi.-primed chain 
elongation products. This probe was synthesized by PCR as described above, 
except for the substitution of digoxigenin-dUTP (Boehringer Mannheim) for 
dTTP. For hybridizations, DNA extracted from the wild-type B. bronchiseptica 
9.73 and from the B. bronchiseptica waaC mutant was digested and transferred to 
nitrocellulose strips (Hybond N; Amersham), as described by Chomczynski (11). 
We then hybridized the digoxigenin-labeled DNA probe to the membranes 
under the conditions specified by the manufacturer and, after blocking nonspe­
cific binding sites, exposed the reacted strips to an antibody against the digoxi- 
genin ligand (Boehringer Mannheim). In order to visualize the positive bands, 
the final color reaction was initiated at alkaline pH by the addition of colorless 
X-phosphate (Boehringer Mannheim) plus tetrazolium blue.
LPS extraction and SDS-PAGE. Cells grown at 36°C in Stainer-Scholte me­
dium were centrifuged (10,000 X g, 15 min, 4°C) and washed twice in distilled 
water. After adjusting the bacterial concentration, we extracted the LPS either by 
the hot phenol-water method (46) along with the modifications previously de­
scribed (24), or by affinity chromatography (41). The procedure employed is 
indicated in the legends to the figures. In both cases the isolated LPS was 
solubilized by heating at 100°C for 5 min in Laemmli sample buffer (28). We then 
applied the LPS suspensions to SDS gels. Gel acrylamide concentrations are 
indicated in the legends to the figures.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed at room 
temperature and constant voltage. The LPS was visualized by the Bio-Rad 
silver-staining technique.
Detection of adenylate cyclase, pertactin, filamentous hemagglutinin, and LPS 
in Western immunoblots. Cells corresponding to 108 CFU of the B. bronchisep­
tica parental strain and the B. bronchiseptica waaC mutant were treated with 
Laemmli sample buffer (28), and the extracts were run on 8 to 25% (wt/vol) 
polyacrylamide-SDS gradient gels. Electrophoresis was performed at room tem­
perature and constant voltage, with molecular weights being estimated by means 
of the Pharmacia calibration kit. After electrophoresis, the proteins were trans­
ferred to nitrocellulose membranes (Hybond C-Super; Amersham) and incu­
bated with either a 1:10,000 dilution of hamster polyclonal immune serum di­
rected against pertactin or a 1:5,000 dilution of mice polyclonal immune serum 
directed against adenylate cyclase or filamentous hemagglutinin of B. bronchi­
septica. Mouse serum (1:500) collected 10 months after infection with wild-type 
B. bronchiseptica 9.73 was also assayed to test its reactivity against LPS isolated 
from either B. bronchiseptica 9.73 or B. bronchiseptica waaC mutants. In all cases, 
we used alkaline phosphatase-labeled sheep anti-mouse immunoglobulins to 
detect the presence of immune complexes.
To obtain the sera, the virulence factors were purified and subsequently inoc­
ulated into BALB/c mice as previously described (19, 20).
Complementation analysis. Parental strain B. bronchiseptica 9.73 DNA was 
partially digested with EcoRI and BamHI. The EcoRI- and RamHI-digested 
fragments were ligated into pJB3Tc (8), digested with EcoRI and BamHI, and 
introduced into competent E. coli S'17-1 by transformation. Transformants were 
grown on LB containing tetracycline (6 pg/ml). Conjugation incubations were 
performed in BGA plus 10 mM MgCl2, using the B. bronchiseptica waaC (Smr, 
Kmr) mutant as the recipient and E. coli S'17-1 containing the recombinant 
replicative plasmid (Tc1-) as the donor and thereafter selected on BGA plus 
tetracycline and streptomycin.
We then analyzed the detergent sensitivity of the resultant colonies of 
transconjugants on Stainer-Scholte solid medium supplemented with 0.02% (wt/ 
vol) SDS. From an SDS-resistant colony, recombinant plasmids, hereafter re­
ferred to as pJB3FS, were isolated. The presence of the waaC gene in such 
plasmids was analyzed by PCR and Southern hybridization.
To clone the waaC gene, the whole gene was amplified by PCR from recom­
binant plasmid pJB3FS using primers totalwaaCf (5'-TGC GAA TTC CCA GCA 
TGT CGC TGA G-3') and totalwaaCr (5'-GCA TGC ACC CAG ACC GAA 
TTC C-3'). The 1,529-bp PCR product was ligated first into pGem-T-Easy 
(Promega) and then into pJB3Tc. The last recombinant plasmid was introduced 
into competent E. coli S17-1 by transformation, and the transformants were 
grown on LB containing tetracycline (6 pg ml-1). Conjugation incubations were 
performed as described above using the B. bronchiseptica waaC (Smr, Kmr) 
mutant as the recipient and E. coli S'17-1 containing the recombinant replicative 
plasmid (Tc1-) as the donor. The transconjugants were thereafter selected on 
BGA plus tetracycline (18 pg ml-1) and streptomycin (200 pg ml-1). We then 
analyzed the detergent sensitivity of transconjugants on Stainer-Scholte solid 
medium supplemented with 0.02% (wt/vol) SDS and the electrophoretic profile 
in SDS-PAGE.
Murine respiratory infection model. Female BALB/c mice 3 to 4 weeks of age 
were used as a model of in vivo respiratory infection by B. bronchiseptica. 
Bacteria grown on BGA were resuspended and adjusted to approximately 107 
CFU ml-1 in phosphate-buffered saline (PBS). Fifty microliters of bacterial 
suspension was delivered intranasally to each mouse via an air displacement 
pipette. At different times postinoculation, three mice from each group were 
sacrificed, and their lungs were removed aseptically. Lungs were homogenized in 
PBS, and appropriate dilutions were plated onto BGA to determine the number 
of viable bacteria present in the lungs. All the experiments were repeated three 
times and gave consistent results.
Tissue culture and determination of bacterial adhesion and persistence. The 
human alveolar cell line A549 (ATCC CCL'185) was used in this study. Cells were 
cultured in Dulbecco’s modified Eagle’s medium (Gibco Laboratories) supple­
mented with 10% fetal calf serum, streptomycin (100 pg ml-1), and ampicillin 
(100 pg ml-1) to 70 to 80% confluence. Twenty-four-well Nunclon Delta tissue 
culture plates (Nunc, Roskilde, Denmark) were seeded with approximately 8 X
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FIG. 1. Construction of a waaC defective mutant in B. bronchiseptica 9.73. Panel A shows the mutagenesis strategy used, based on site-specific 
recombination of the nonreplicative vector pKlSmob. The internal 200-bp DNA fragment of the waaC coding region used in this strategy was 
obtained by PCR using primers waaCpf and waaCpr7 as indicated in Materials and Methods. Panel B shows the Southern blot analysis that confirmed 
the genetic structure of the mutant B. bronchiseptica LP39. Total DNA from B. bronchiseptica 9.73 and B. bronchiseptica LP39 was digested with 
EcoRI and probed with the 200-bp waaC PCR product labeled with digoxigenin.
104 cells per well 18 h before the assay. For adhesion assays, cells were seeded on 
glass coverslips previously placed in the selected wells.
Bacterial strains (either wild type or mutant) were grown for 16 h on SS 
medium, washed, and suspended in Dulbecco’s modified Eagle’s medium sup­
plemented with 10% fetal calf serum without antibiotics to an optical density of 
0.5 at 650 run. Then 8 X 106 bacteria in 0.5 ml were added to the wells (ratio of 
bacteria to cells, 100:1) and centrifuged onto adherent cells at 300 X g. After 2 h 
at 37°C in 5% CO2, the monolayers were washed at least five times with PBS (pH 
7.2).
To determine bacterial adhesion, the cells grown on glass coverslips with 
attached bacteria were fixed in methanol, and the staining of cells and bacteria 
was done with crystal violet (0.07% in water). Examination was carried out using 
phase-contrast microscopy at l,000X magnification. Approximately 50 cells were 
examined to calculate the number of adherent bacteria per epithelial cell. All 
experiments were done at least three times in duplicate.
To determine bacterial survival within the alveolar cell, after the 2-h incuba­
tion period and the extensive washing described above, the monolayers were 
further incubated for 3 h at 37°C in 5% CO2 to allow bacterial invasion. The 
medium was then replaced with 0.5 ml of complete medium containing 100 |jbg of 
polymyxin B ml-1 and then incubated for 1 h at 37°C in 5% CO2 to kill 
extracellular bacteria (9). When B. bronchiseptica alone was treated with this 
level of polymyxin B, 99.999% of the bacteria were killed over a 1-h period.
Following incubation, the polymyxin B was removed by extensive washing and 
replaced by 0.5 ml of Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal calf serum, streptomycin (100 |xg ml-1), and ampicillin (100 |xg ml-1). 
The medium was changed every 24 h. At selected time periods, cells containing 
viable intracellular organisms were recovered from the trypsin-treated and 
stripped monolayers. Trypan blue dye exclusion was used to check eukaryotic cell 
viability. Intracellular bacteria were counted by plating appropriate dilutions 
onto BGA. The number of CFU per alveolar cell was then calculated. Each 
strain was tested in triplicate.
Statistical analysis. Means and standard deviations were calculated from 
log10-transformed numbers of CFU. Differences between means were assessed 
by two-tailed Student’s t tests, with significance accepted at the P < 0.05 level.
RESULTS
Cloning of an internal region of the waaC gene of B. bron­
chiseptica. We amplified a defined 200-bp internal region of the 
waaC gene of B. bronchiseptica by PCR. By DNA sequencing, 
we observed that the amplified product reflected a faithful 
replication of the 200-bp region of the gene spanned by the 
14-base stretches complementary to the two primers (waaCpf 
and waaCpr), according to previously published data (Gen- 
Bank). This sequence within the waaC gene of B. bronchisep­
tica 9.73, in turn, exhibits 97% identity with B. bronchiseptica 
cosmid BbLPSl (AJ007747), 97% with the homologous region 
from the B. pertussis LPS biosynthesis locus (X90711), and 
54% identity with the corresponding Escherichia coli heptosyl I 
transferase waaC gene (AF019746).
We generated a deep rough mutant by effecting a site-spe­
cific integration through conjugation with E. coli containing the 
recombinant plasmid pKlSmob waaC (Fig. 1A). Since deter­
gent sensitivity should also become altered in such a deep 
rough mutant (36), we confirmed that the resulting streptomy­
cin- and kanamycin-resistant genomic transconjugants were
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FIG. 2. SDS-PAGE profiles and immunoblot analyses of phenol- 
water-extracted LPS from wild-type B. bronchiseptica and B. bronchi- 
septica waaC mutant LP39. (A) Silver-stained SDS-PAGE (8 to 25% 
[wt/vol]) of LPS extracted from wild-type B. bronchiseptica in virulent 
phase (lane 1) and from a waaC mutant in virulent culture conditions 
(lane 2). (B) Immunoblots of the SDS-PAGE gel shown in panel A. 
The gel blot was exposed to mouse antiserum obtained 10 months after 
infection with wild-type B. bronchiseptica as the primary antibody. LPS 
samples corresponded in all cases to material extracted from approx­
imately 1 mg (wet weight) of bacterial cells. KDO, 3-deoxy-D-znanno- 
octulosonic acid.
unable to grow on Stainer-Scholte solid medium supplemented 
with 0.02% (wt/vol) SDS.
Southern transfer analysis. We digested DNA from the 
wild-type strain and from the B. bronchiseptica waaC mutant 
with EcoRI, an enzyme that recognizes a single site in the 
nonrecombined pK18mob suicide plasmid, and then separated 
the resulting total DNA digests by agarose gel electrophoresis. 
We then exposed the electrophoresed gels to a ivuuC-specific 
digoxigenin-DNA probe. Subsequent treatment of the labeled 
gels with digoxigenin-specific antibodies indicated probe hy­
bridization to a single Leo RI fragment within the samples from 
the parental strain, with this species being replaced by two 
fragments of smaller size in the waaC mutants (Fig. IB). As 
expected, we observed that the sum of the sizes of the two 
waaC fragments (approximately 4,200 and 6,300 kb) corre­
sponded to the size of the parental-strain single fragment (ap­
proximately 6,800 kb) plus the size of the vector (approximate­
ly 3,700 kb). This result confirmed the correct insertion of the 
waaC recombinant plasmid into the B. bronchiseptica chromo­
some after the conjugation event.
For the following studies, we selected one of the confirmed 
waaC mutants, hereafter referred to as the B. bronchiseptica 
LP39 mutant.
LPS electrophoresis and immunoblotting. We analyzed the 
LPS phenotype of B. bronchiseptica LP39 by SDS-PAGE using 
silver staining (Fig. 2A). The LPS profile from B. bronchisep­
tica LP39 exhibited no O-antigen band; moreover, only a single 
LPS band was present, which migrated considerably faster than 
the corresponding wild-type species. These electrophoretic 
properties are consistent with the deep rough phenotype. Fur­
thermore, when we carried out immunoblots of these LPS 
species using sera from B. bronchiseptica-infected mice, we 
observed that the wild-type LPS was serologically recognized, 
whereas the mutant LPS was not (Fig. 2B).
Characterization of expression of virulence determinants in 
B. bronchiseptica LP39. In order to evaluate if B. bronchiseptica 
LP39 still had the ability to respond to well-known virulence 
phase modulatory influences such as low temperature and sul-
FIG. 3. Semiquantitative analysis of virulence determinant expres­
sion in wild-type B. bronchiseptica and in the B. bronchiseptica waaC 
mutant B. bronchiseptica LP39 by immunoblotting. (A) SDS-PAGE (8 
to 25% [wt/vol]) of bacterial lysates corresponding to 108 CFU of 
wild-type B. bronchiseptica in avirulent phase (lane 1 ), B. bronchiseptica 
in virulent phase (lane 2), and B. bronchiseptica waaC mutant LP39 in 
virulent culture conditions (lane 3 ). Proteins were stained overnight in 
an aqueous solution of Coomassie brilliant blue R250 (0.2% [wt/vol]). 
(B to D) Western blots of the SDS-PAGE gel shown in panel A. 
Antisera against adenylate cyclase (B), filamentous hemagglutinin (C), 
and pertactin (D) were used.
fate anion, we incubated both wild-type and recombinant bac­
teria at 25°C in either BGA alone or BGA supplemented with 
40 mM MgSO4 and used hemolytic activity as a marker of 
virulence. After 48 h of exposure to sulfate under those con­
ditions, both the wild-type strain and the B. bronchiseptica 
LP39 mutant shifted from a virulent to an avirulent state (data 
not shown). At 36°C, both strains had approximately the same 
diameter of hemolysis in BGA. These findings indicate that the 
bvgAS two-component regulatory system remains functional in 
the waaC mutants.
We then performed a semiquantitative analysis of the ex­
pression of virulence determinants by Western blotting, using 
mouse polyclonal immune sera directed against purified ade­
nylate cyclase, pertactin, and filamentous hemagglutinin (Fig. 
3). Although a decrease in both filamentous hemagglutinin and 
pertactin could be observed in the B. bronchiseptica LP39 mu­
tant lysates, in the case of pertactin the decrease in intensity 
was especially notable (Fig. 3).
Complementation of the waaC mutant phenotype. The B. 
bronchiseptica LP39 mutant displayed an alteration in its LPS 
profile upon SDS-PAGE and an enhanced sensitivity to SDS. 
To rule out the possibility that these phenotypes were due to 
some uncontrolled polar effect, we obtained a clone that com­
plements in trans the defect in LPS caused by the insertion of 
the pK18mob::wuC recombinant plasmid. The DNA region 
contained in plasmid pJB3FS complemented both the alter­
ation in the SDS-PAGE profile (Fig. 4) and the SDS sensitivity 
(not shown) of the B. bronchiseptica LP39 mutant strain. In 
addition, we were able to amplify a DNA fragment with the 
expected size (1,529 bp) using the totalwaaCf and totalwaaC,. 
primers.
Survival ofB. bronchiseptica LP39 mutant within the murine 
respiratory tract. Nonlethal doses of the B. bronchiseptica 
LP39 mutant strain were administered to BALB/c mice intra-
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FIG. 4. SDS-PAGE (18% [wt/vol]) analysis showing the genetic 
complementation of the waaC mutant B. bronchiseptica LP39 with the 
genomic library of the parental strain. Each well contained LPS ex­
tracted from the wild-type B. bronchiseptica strain (lane 1), waaC 
mutant B. bronchiseptica LP39 carrying the pJB3FS recombinant plas­
mid (lane 2), and waaC mutant B. bronchiseptica LP39 (lane 3). The 
samples were obtained from around 1 to 2 mg (wet weight) of bacterial 
cells using EDTA and polymyxin B as described in Materials and 
Methods. The positions of the main LPS components in the gel are 
indicated to the left. KDO, 3-deoxy-n-/w/////o-octulosonic acid.
nasally, and the number of CFU present in the lungs was 
measured at different time points following infection (Fig. 5). 
Although the wild-type strain showed a classic pattern of in­
fection (19), the mutant strain was unable to survive, being 
effectively cleared within 5 days. Wild-type bacteria could still 
be recovered from the infected mice’s lungs 30 days after 
inoculation. This deficiency of B. bronchiseptica LP39 in mouse 
colonization was completely restored by complementation with 
the DNA region contained in plasmid pJB3FS. In this exper­
iment, B. bronchiseptica LP39 harboring the replicative plas­
mid pJB3FS displayed a lung colonization profile statistically 
indistinguishable from that of the parental strain.
In order to analyze the behavior of the mutant at late stages 
FIG. 5. In vivo persistence of wild-type B. bronchiseptica 9.73 and B. bronchiseptica waaC mutant LP39 in a murine respiratory model. Lungs 
were extracted at different times, and the number of viable bacteria per lung was determined. The results represent the means ± standard deviation 
of three independent experiments.
of infection, we tried to overcome the colonization deficiency 
of B. bronchiseptica LP39 by performing coinoculation exper­
iments in which the parental and mutant strains were inocu­
lated with a delay of 1 h. In this kind of experiment, the 
parental strain inoculated first could suppress the colonization 
deficiency of B. bronchiseptica LP39, as demonstrated for other 
microorganism-host interactions (18). The parental and B. 
bronchiseptica LP39 colonies were distinguished by differential 
antibiotic sensitivity; the parental strain was Smr, while B. 
bronchiseptica LP39 was Sm1 and Km1. Again, B. bronchiseptica 
LP39 was cleared within 5 days following the infection (data 
not shown).
To determine whether the first-inoculated strain precludes 
the colonization of the second one, we performed an indepen­
dent coinoculation experiment in which the second inoculation 
was performed with a labeled parental strain carrying plasmid 
pGB5Pl as a marker, to differentiate it from the first inoculum. 
In this case, the colonization kinetics of labeled B. bronchisep­
tica exhibited the observed pattern of parental strain infection 
(data not shown).
We also varied the delay (5 to 20 days) between the first and 
second inoculum. Interestingly, we did not detect significant 
changes in the results obtained with either the mutant or the 
labeled wild-type strains even in those experiments, in which 
the second inoculation was performed as late as 20 days after 
the first one. These data seem to indicate that under our 
experimental conditions, no protection was induced after 20 
days of infection.
Adhesion and intracellular survival of parental and B. bron­
chiseptica LP39 mutant strains. In vitro assays demonstrated 
that the adherence of B. bronchiseptica LP39 to human pul­
monary epithelial cells (5 ± 4 bacteria/epithelial cell) was sig­
nificantly lower than that exhibited by the parental strain (62 ±
B. bronchiseptica parental strain.
B. bronchiseptica waaC mutant.
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FIG. 6. Phase-contrast micrographs of the adherence of B. bronchiseptica strains to human A549 alveolar epithelial cells, used in a standard 
adherence assay with (A) the parental strain and (B) the waaC mutant B. bronchiseptica LP39. Magnification, I,()()() x. Panels are representative 
of one to three independent experiments.
25 bacteria/epithelial cell) (Fig. 6). The waaC mutant also 
showed a lower invasion rate than the parental strain. This 
result was more likely to be caused by the reduced number of 
attached bacteria than by a defect in bacterial invasive ability.
However, this last possibility could not be ruled out in our 
system.
For both bacteria, intracellular survival showed the same 
profile over time. A decrease in bacterial viability was observed
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FIG. 7. Intracellular survival of B. bronchiseptica wild-type strain and B. bronchiseptica waaC mutant LP39 in the human alveolar epithelial cell 
line A549. At selected time periods, the number of CFU per alveolar cell was determined. The data represent the means ± standard deviation 
of three independent experiments.
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during the first days postinvasion (Fig. 7), after which both the 
mutant and the parental strain showed a constant increase in 
the number of live bacteria per eukaryotic cell during the 
course of the experiment.
DISCUSSION
LPS has been shown to be important for virulence in many 
bacterial pathogens, and its contribution to the infection cycle 
by a variety of mechanisms, including antigenic variation, mo­
lecular mimicry, and induction of blocking antibodies, has been 
proposed (30, 31, 43). In Bordetella, however, the role of LPS 
during infection has been little investigated. In recent studies, 
Spears et al. (38) isolated and characterized in vitro and in vivo 
two LPS wlb mutants of Bordetella avium. These LPS mutants 
were affected in their ability to colonize turkey trachea. In 
addition, wlb deletion mutants of three other species of Bor­
detella, B. pertussis, B. parapertussis, and B. bronchiseptica, were 
also described. In that work, the authors showed that the bio­
synthesis of a full-length LPS molecule by these three species 
of bordetellae is essential for the expression of full virulence in 
mice. West et al. (46) described an LPS mutant of B. bronchi­
septica resulting from an insertion in the phosphoglucomutase- 
encoding gene (BB7865pgm). This mutant showed a dimin­
ished ability to survive either in vitro or in vivo following 
intranasal infection of mice. However, none of these reports 
described the in vitro or in vivo role of deep rough LPS, a 
phenotype observed during human B. bronchiseptica infection, 
in the interaction with host cells.
Here we have approached the construction of a waaC mu­
tant of B. bronchiseptica on the basis of genetic alterations that 
in other gram-negative bacteria have been shown to produce a 
deep rough LPS structure compatible with bacterial viability. 
The resulting waaC mutation of B. bronchiseptica was not le­
thal, and the altered bacteria were still able to produce detect­
able levels of the major virulence factors adenylate cyclase, 
filamentous hemagglutinin, and pertactin (Fig. 3) and re­
sponded to well-known modulators of the bvgAS system, such 
as low temperature and sulfate ion. These observations indi­
cate that the bvgAS sensor and response regulator functions 
remain unaltered even within the context of a deep rough LPS 
mutation.
We observed that the mutation in the waaC gene of B. 
bronchiseptica reduced the expression of pertactin and to a 
lesser extent of filamentous hemagglutinin. Since all of these 
proteins are related to the outer membrane, the alteration of 
this cellular compartment by changes in the structure of the 
LPS could explain the observed protein reduction levels. This 
decrease in virulence factors might favor the persistence of the 
bacteria within the host during chronic manifestations of B. 
bronchiseptica infection. Indeed, the production of fevg-acti- 
vated gene products may be a disadvantage in terms of the 
intracellular survival of the bacteria, since the expression of 
certain virulence factors is highly toxic to the infected eukary­
otic cells (1, 5, 17).
Interestingly, the LPS from the mutant B. bronchiseptica 
LP39 was immunologically different from the wild-type LPS. 
Accordingly, the waaC mutation that exhibits no O-antigen 
determines a complete loss of LPS serologic reactivity (Fig. 
2B), including that of the higher-mobility component, which is 
strongly reactive within the LPS of the parental strain (Fig. 
2B). These results resemble those observed during chronic 
infections in which sera that still react with intact B. bronchi­
septica LPS isolated from early stages of infection failed to 
immunologically recognize the deep rough LPS of bacteria 
isolated from the same human infections (data not shown).
Our results from the murine respiratory infection model 
clearly demonstrated that the deep rough phenotype of the 
LPS diminishes B. bronchiseptica's ability to colonize mice. The 
B. bronchiseptica LP39 mutant was cleared from lungs within 5 
days, whereas the parental strain persisted for at least 30 days 
postinfection (Fig. 5). This decrease in colonization ability 
could not be overcome by coinfection experiments with the 
parental strain, indicating that the waaC phenotype cannot be 
complemented with wild-type LPS, which has been shown to be 
released into the surrounding medium (25).
These data point out that the B. bronchiseptica LP39 mutant, 
either alone or in combination with the wild-type strain, is 
unable to colonize mouse lungs and suggest that the observed 
deep rough LPS phenotype isolated from chronic infections 
(20, 21) would not come from mutants that infected the host 
from the beginning. By contrast, these deep rough bacteria 
would have arisen from already established infections.
In agreement with this inability to colonize, the B. bronchi­
septica LP39 mutant attaches to pulmonary cells less efficiently 
than the wild-type strain. However, persistence kinetics of both 
strains within the eukaryotic cells showed similar patterns over 
the time period studied. Figure 7 shows an initial decrease in 
bacterial survival, which could suggest a lag period in which the 
bacteria have to adapt to environmental conditions, followed 
by a significant increase in the number of live bacteria per 
eukaryotic cell over time.
These results suggest that both strains of B. bronchiseptica 
are able not only to survive but also to replicate inside pulmo­
nary cells. After 14 days, significant eukaryotic cell death was 
detected. A similar cell death rate was found in both infected 
and noninfected (control) cells, indicating that death was not 
caused by B. bronchiseptica infection. Due to these circum­
stances, in vitro studies could not be performed for more than 
2 weeks, which excludes the possibility of a long-term survival 
comparison of the strains.
According to our results, the truncated form of B. bronchi­
septica LPS isolated from chronic human infections and animal 
infections (20, 21, 29) can only be explained if we assume that 
they derive from smooth forms which were able to colonize. 
The concomitant modification of the expression pattern of the 
principal virulence factors and the complete loss of LPS sero­
logic reactivity in the waaC mutant underscore the idea that 
structural changes that could occur during infection help bac­
teria to persist within the host.
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